The Addition of Intrathecal Clonidine to Reduce Medication-Related Side-Effects in Cancer Pain: A Retrospective Cohort Study
While its role in reducing pain and systemic opioids is complex, IT clonidine may have a beneficial role in mitigating medication-related side-effects from systemic opioids, IT opioids, or LA for cancer pain. IT clonidine may be safely initiated at doses of 40-60 mcg/day for this indication.
Authors
- Rahul Chaturvedi (ORCID: https://orcid.org/0000-0001-6324-0771)
- Peyton Johnson (ORCID: https://orcid.org/0000-0003-0210-3794)
- Neal Rakesh (ORCID: https://orcid.org/0000-0003-0197-5240)
- Evgeny Bulat (ORCID: https://orcid.org/0000-0002-8444-0067)
- Amitabh Gulati (ORCID: https://orcid.org/0000-0003-1654-8639)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- Presbyterian Hospital (US)
- Medical Advanced Pain Specialists (US)
Publication Details
- Journal
- Journal of Pain Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/jpr.s504556
- Citations
- 4
- Primary Topic
- Pain Management and Opioid Use
- Type
- article
- Field-Weighted Citation Impact
- 8.76
Funders
- National Institutes of Health